Biocon Overview
- Year Founded
-
1978
- Status
-
Public
- Employees
-
9,805
- Stock Symbol
-
532523
- Investments
-
17
- Share Price
-
$3.84
- (As of Wednesday Closing)
Biocon General Information
Description
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
Contact Information
Website
www.biocon.comCorporate Office
- 20th KM, Hosur Road
- Electronic City
- Bengaluru, Karnataka 560100
- India
Corporate Office
- 20th KM, Hosur Road
- Electronic City
- Bengaluru, Karnataka 560100
- India
Biocon Stock Performance
As of 16-Apr-2025, Biocon’s stock price is $3.84. Its current market cap is $4.6B with 1.2B shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.84 | $3.83 | $3.11 - $4.72 | $4.6B | 1.2B | 148K | $0.08 |
Biocon Financials Summary
As of 31-Dec-2024, Biocon has a trailing 12-month revenue of $1.74B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 7,415,311 | 6,147,060 | 3,320,878 | 5,559,064 |
| Revenue | 1,739,784 | 1,714,762 | 1,361,693 | 1,077,045 |
| EBITDA | 493,233 | 471,953 | 288,526 | 235,251 |
| Net Income | 96,120 | 123,511 | 57,623 | 87,025 |
| Total Assets | 6,723,629 | 6,338,875 | 2,689,497 | |
| Total Debt | 0 | 1,951,795 | 2,194,711 | 678,718 |
Biocon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biocon Comparisons
Industry
Financing
Details
Biocon Competitors (35)
One of Biocon’s 35 competitors is Lupin, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lupin | Corporation | Mumbai, India | ||||
| Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA |
Biocon Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biocon Patents
Biocon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3230949-A1 | Preparation method of echinocandin nucleus | Pending | 07-Sep-2021 | ||
| AU-2022342798-A1 | Preparation method of echinocandin nucleus | Pending | 07-Sep-2021 | ||
| JP-2024531610-A | Method for preparing echinocandin core | Pending | 07-Sep-2021 | ||
| EP-4399296-A1 | Preparation method of echinocandin nucleus | Pending | 07-Sep-2021 | ||
| CA-3228669-A1 | Purification of liraglutide | Pending | 10-Aug-2021 | C07K14/605 |
Biocon Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biocon Investments & Acquisitions (17)
Biocon’s most recent deal was a Corporate Asset Purchase with Eywa Pharma (New Jersey facility) for . The deal was made on 02-Sep-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eywa Pharma (New Jersey facility) | 02-Sep-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Mylan (Biosimilar Businesses) | 29-Nov-2022 | Merger/Acquisition | Pharmaceuticals | ||
| AMPYR Renewable Energy Resources Eleven | 29-Jun-2022 | Secondary Transaction - Private | Special Purpose Acquisition Company (SPAC) | ||
| Bicara Therapeutics | 15-Mar-2021 | Seed Round | Drug Discovery | ||
| Cyclops Medtech | 23-Dec-2020 | Grant | Diagnostic Equipment |
Biocon ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
24.58 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Biocon Exits (2)
Biocon’s most recent exit was on 30-Sep-2009 from IDL Specialty Chemicals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| IDL Specialty Chemicals | 30-Sep-2009 | Completed |
|
||
| axicorp | 11-Feb-2008 | Merger/Acquisition | Completed |
Biocon Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Biocon Biologics | Bengaluru, India | 1978 |
Biocon FAQs
-
When was Biocon founded?
Biocon was founded in 1978.
-
Where is Biocon headquartered?
Biocon is headquartered in Bengaluru, India.
-
What is the size of Biocon?
Biocon has 9,805 total employees.
-
What industry is Biocon in?
Biocon’s primary industry is Biotechnology.
-
Is Biocon a private or public company?
Biocon is a Public company.
-
What is Biocon’s stock symbol?
The ticker symbol for Biocon is 532523.
-
What is the current stock price of Biocon?
As of 16-Apr-2025 the stock price of Biocon is $3.84.
-
What is the current market cap of Biocon?
The current market capitalization of Biocon is $4.6B.
-
What is Biocon’s current revenue?
The trailing twelve month revenue for Biocon is $1.74B.
-
Who are Biocon’s competitors?
Lupin, Intas Pharmaceuticals, Merck & Co., Roche, and Coherus Biosciences are some of the 35 competitors of Biocon.
-
What is Biocon’s annual earnings per share (EPS)?
Biocon’s EPS for 12 months was $0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
